Publications by authors named "Alexis Talbot"

Claim this Profile
R
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study.
Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.
Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Ananya Kannan, Alexis Talbot

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Phenotype and Clinical Outcomes in Randall Disease versus Light-Chain Amyloidosis.
Martin Nicol, Camille Cohen, Alexis Talbot, Mathilde Baudet, Stephanie Harel

Amyloid· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling and risk stratification in solitary bone plasmacytoma.
Barbara Burroni, Stéphanie Harel, Raphaele Seror, Sophia Ascione, Youlia Kirova, Alexis Talbot

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated epigenetic and genetic programming of primary human T cells.
Laine Goudy, Alvin Ha, Ashir A Borah, Jennifer M Umhoefer, Lauren Chow, Alexis Talbot

Nat Biotechnol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.
Vincent Allain, Allison G Rothrock, Pierre-Louis Bernard, William A Nyberg, Alexis Talbot

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Sarah Cayla, Lionel Karlin, Jerome Lambert, Anne Lazareth, Alexis Talbot

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature.
Carla Cicerchia, Tristan Vaugeois, Nathalie Forgeard, Jean-François Alexandra, Floriane Theves, Alexis Talbot

Immunotherapy· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome.
Alexis Talbot, Nathalie Forgeard, Tristan Vaugeois, Floriane Theves, Sabrine Dimassi

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years.
Alexis Talbot, Pierre-Edouard Debureaux, Agnès Lillo-Le Louet, Yasmine Derri, Marine Aroux-Pavard

Ther Adv Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort.
Pierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, Marie Passet, Marie Templé, Alexis Talbot

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Serum hyperviscosity syndrome: Update 2024].
Pierre-Edouard Debureaux, Nathalie Parquet, Anne C Brignier, Dikelele Elessa, Virginie Lemiale, Alexis Talbot

Rev Med Interne· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study.
Martin Nicol, Cassiel Kitzinger, Mathilde Baudet, Alyssa Faradji, Théo Pezel, Alexis Talbot

Amyloid· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study.
Axel André, Lydia Montes, Damien Roos-Weil, Laurent Frenzel, Marguerite Vignon, Alexis Talbot

Hemasphere· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma.
Nathalie Roders, Cecilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Alexis Talbot

Cancer Immunol Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Nathalie Forgeard, Dikélélé Elessa, Alexander Carpinteiro, Karim Belhadj, Monique Minnema, Alexis Talbot

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.
Pierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, Stéphanie Harel, Laurent Frenzel, Alexis Talbot

Haematologica· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming proteasome inhibitor resistance in the immunotherapy era.
Bonell Patiño-Escobar, Alexis Talbot, Arun P Wiita

Trends Pharmacol Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
Ophélie Champion, Alana Soler, Sophie Maïga, Céline Bellanger, Catherine Pellat-Deceunynck, Alexis Talbot

Front Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological characteristics of light chain crystalline podocytopathy.
Samih H Nasr, Satoru Kudose, Vincent Javaugue, Stéphanie Harel, Samar M Said, Alexis Talbot

Kidney Int· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evolved AAV variant enables efficient genetic engineering of murine T cells.
William A Nyberg, Jonathan Ark, Angela To, Sylvanie Clouden, Gabriella Reeder, Alexis Talbot

Cell· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study.
Pierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, Virginie Lemiale, Virginie Siguret, Alexis Talbot

Front Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis